New drug BGM-2121 enters first human tests for advanced cancers

NCT ID NCT07346846

Recruiting now Disease control Sponsor: BioGate Precision Medicine Corp. Source: ClinicalTrials.gov ↗

First seen Feb 01, 2026 · Last updated Apr 30, 2026 · Updated 10 times

Summary

This early-phase study tests a new drug called BGM-2121 in about 35 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to check the drug's safety and find the best dose. This is a first-in-human trial, so it focuses on side effects and how the body handles the drug, not on curing the cancer.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

National Cheng Kung University Hospital
NOT_YET_RECRUITING

Tainan, Taiwan

Contact Phone: •••-•••-•••• Email: •••••@•••••
National Taiwan University Hospital
NOT_YET_RECRUITING

Taipei, Taiwan

Contact Phone: •••-•••-•••• Email: •••••@•••••
Taipei Veterans General Hospital
RECRUITING

Taipei, Taiwan

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

ADVANCED SOLID TUMORS ADVANCED SOLID TUMORS